Evidence map›Paper›PMID 37101856›Full record

Trial reportInternational journal of clinical practice2023

Effect of

Zahra Vahedpoorfard, Samira Ferdosi, Habibollah Rahimi, Hossein Motedayyen

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of clinical practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Effect ofInternational journal of clinical practice · 2023
    Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Zahra VahedpoorfardAutoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.
Samira FerdosiDepartment of Obstetrics and Gynecology, Kashan University of Medical Sciences, Kashan, Iran.ORCID https://orcid.org/0009-0005-1057-9882
Habibollah RahimiDepartment of Biostatics and Epidemiology, School of Public Health, Kashan University of Medical Sciences, Kashan, Iran.
Hossein MotedayyenAutoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.ORCID https://orcid.org/0000-0002-7372-4590
Kashan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Female sexual dysfunction is a common distressing problem among women, which may result from reducing circulating endogenous estrogen. Methods: In the current randomized clinical trial, study populations consisted of 63 postmenopausal women who were randomly categorized into two groups. In the hop group ( Results: No statistically significant differences in FSFI scores (sexual desire, sexual arousal, vaginal lubrication, satisfaction, orgasm, sexual pain, and total FSFI) ( Conclusion: Vaginal hop was as effective as estradiol in improving the sexual dysfunction among postmenopausal women with no adverse events. This trial is registered with IRCT20210405050859N1.

Indexed as

HumulusSexual Dysfunction, PhysiologicalEstradiolFemaleHumansPostmenopauseSexual BehaviorEstradiol

Identifiers

PMID37101856
PMCPMC10125751
OpenAlexW4366202269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.